文献速递骨软组织肉瘤与黑色素瘤

专家组织病理学评估与分子分析用于疑难皮肤黑色素细胞肿瘤

Expert Histopathologic Evaluation and Molecular Analyses for Ambiguous Cutaneous Melanocytic Tumors.
PubMed 文献 · J Clin Oncol · 2026-10-15

这项前瞻性队列研究纳入994例病理学家判定为疑难的原发性皮肤黑色素细胞肿瘤患者,采用专家组织病理学评估及不确定时的分子分析进行逐步诊断。966例(97.2%)获得明确诊断,中位随访约5年显示非黑色素瘤组无黑色素瘤相关事件,支持该诊断路径的临床有效性。

要点

  • 专家病理联合分子分析使97.2%疑难黑色素细胞肿瘤获得明确诊断。
  • 诊断为非黑色素瘤者随访5.4年无黑色素瘤相关事件(0.0%,95%CI 0.0-0.6)。
  • 诊断为黑色素瘤者5年累积事件发生率5.7%(95%CI 3.3-8.1)。

核心结论

  • 专家组织病理学评估联合分子分析可为几乎所有疑难原发性皮肤黑色素细胞肿瘤提供明确诊断。
  • 长期随访支持该逐步诊断策略的临床有效性。

研究设计与样本

  • 肿瘤先接受专家组织病理学评估,不确定时补充下一代测序、单核苷酸多态性阵列和靶向RNA测序。
  • 全国258562例切除黑色素细胞肿瘤患者中2685例(1.0%)为疑难肿瘤。

主要发现

  • 966例(97.2%)获得诊断,其中417例(42.0%)仅凭专家组织病理学评估确诊,549例(55.2%)经补充分子分析确诊。
  • 608例(61.2%)诊断为非黑色素瘤,中位随访5.4年无黑色素瘤相关事件(发生率0.0%,95%CI 0.0-0.6)。
  • 358例(36.0%)诊断为黑色素瘤,其中186例中33例(17.7%)前哨淋巴结活检阳性,中位随访5.0年20例发生黑色素瘤相关事件(累积发生率5.7%,95%CI 3.3-8.1)。
  • 28例(2.8%)诊断为交界性黑色素瘤,随访期间无事件发生。

临床怎么用

  • 对病理学家判定为疑难的皮肤黑色素细胞肿瘤,推荐转诊至专家皮肤病理中心进行多学科评估。
  • 专家评估不确定时,可逐步补充下一代测序、单核苷酸多态性阵列和靶向RNA测序以辅助分类。
  • 明确诊断为非黑色素瘤的患者长期黑色素瘤相关事件风险极低,支持该诊断路径用于临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A subset of cutaneous melanocytic tumors has ambiguous histopathologic features that preclude reliable classification as benign or malignant. We evaluated the diagnostic yield and long-term clinical validity of expert histopathologic evaluation and, when inconclusive, additional molecular analyses in patients with ambiguous primary cutaneous melanocytic tumors. METHODS: In this prospective cohort study, consecutive patients with primary cutaneous melanocytic tumors deemed ambiguous by referring pathologists were evaluated at a tertiary dermatopathology referral center in the Netherlands from September 2018 through December 2021. Tumors underwent expert histopathologic evaluation, with next-generation sequencing, single-nucleotide polymorphism array, and targeted RNA sequencing when inconclusive. Tumors were classified as nonmelanoma, melanoma, or borderline melanoma. Clinical validity was assessed by melanoma-related events during follow-up. RESULTS: Among 258,562 patients with excised melanocytic tumors nationwide, 2,685 (1.0%) had ambiguous tumors. We included 994 patients and reached a diagnosis in 966 (97.2%): 417 (42.0%) after expert histopathologic evaluation alone and 549 (55.2%) after additional molecular analyses. Among 608 patients (61.2%) with a nonmelanoma diagnosis, no melanoma-related events occurred during median follow-up of 5.4 years (incidence, 0.0%; 95% CI, 0.0 to 0.6). Among 358 patients (36.0%) with a melanoma diagnosis, 33 of 186 (17.7%) had a positive sentinel node biopsy, and 20 developed melanoma-related events during median follow-up of 5.0 years (cumulative incidence, 5.7%; 95% CI, 3.3 to 8.1). No events occurred in 28 patients (2.8%) with a borderline melanoma diagnosis. CONCLUSION: Expert histopathologic evaluation combined with molecular analyses provided a definitive diagnosis in nearly all patients with ambiguous primary cutaneous melanocytic tumors. Long-term follow-up supported the clinical validity of this stepwise diagnostic approach.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ebbelaar CF, Lensing AWA, Breimer GE, et al. Expert Histopathologic Evaluation and Molecular Analyses for Ambiguous Cutaneous Melanocytic Tumors. J Clin Oncol. 2026. PMID: 42879715. doi:10.1200/JCO-26-00432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。